NEW YORK (GenomeWeb News) — Ciphergen’s sale of its proteomics tools business to Bio-Rad did not close on Nov. 1 as originally expected.
After Ciphergen’s shareholders approved the sale last week the company said it expected the transaction to close before Nov. 1. But as of yesterday the deal had not closed.
A Bio-Rad spokeswoman declined to comment on the delay but said Wednesday that the deal could be finished within the next few days.